MorphoSys releases update on drug pipeline

MorphoSys AG recently provided an update on the clinical development outlook for its proprietary drug pipeline.

MorphoSys has created one of the largest and most distinguished biopharmaceutical pipelines in the biotechnology sector. MorphoSys said it plans to commit additional resources to advance its programs through approval-enabling studies and become a commercial organization.

"MorphoSys has successfully transitioned from a technology provider to a drug development organization,” Simon Moroney, CEO of MorphoSys AG, said. “With a robust set of proprietary drug candidates, now is the time to scale our investment to ensure that we capture the full value of our portfolio.”

Currently, MorphoSys is concentrated on three clinical candidates: the hemato-oncology programs MOR208 and MOR202, and the prostate cancer program MOR209/ES414, which is being co-developed with Emergent BioSolutions.

In 2016, MorphoSys is also planning to begin clinical studies of MOR106 and MOR107 in inflammatory and fibrotic indications.

“We aspire to become a fully-integrated and commercial biopharmaceutical organization with our own products on the market,” Moroney said. “Our lead cancer compound MOR208, for which we have a comprehensive development plan, will be at the forefront of this process."

The company also plans to continue investment in technology leadership directed at creating more clinical development programs.

“MorphoSys has established a broad network of relationships with big pharma, biopharma companies of various sizes and academia that could generate a stream of attractive product opportunities,” Marlies Sproll, chief scientific officer of MorphoSys, said.